Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.76 |
| ▸ | CA1 | P00915 | 5/20 | 0.76 |
| ▸ | CA2 | P00918 | 5/20 | 0.76 |
| ▸ | CA9 | Q16790 | 5/20 | 0.76 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.76 |
| ▸ | CA6 | P23280 | 4/20 | 0.76 |
| ▸ | CA7 | P43166 | 4/20 | 0.76 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.76 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.76 |
| ▸ | CA5A | P35218 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | CA4 | P22748 | 1/20 | 0.76 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.76 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.76 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.76 |
| ▸ | APP | P05067 | 9/20 | 0.64 |
| ▸ | AQP1 | P29972 | 1/20 | 0.62 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21019469 | 0.91 | CA12 (0.74) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL5153664 | 0.91 | CA12 (0.74) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL229243 | 0.91 | CA1 (0.74) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL231262 | 0.91 | CA12 (0.74) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL2957873 | 0.91 | CA12 (0.66) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL2959448 | 0.90 | CA12 (0.65) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL4017488 | 0.90 | CISD1 (0.73) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL4412903 | 0.90 | CISD1 (0.76) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL230392 | 0.90 | APP (0.79) | CA12CA1CA2CA9CISD1 | |
| SCHEMBL17000509 | 0.89 | CA12 (0.71) | CA12CA1CA2CA9CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311727-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7763612-B2 | Therapeutic amine-arylsulfonamide conjugate compounds | ALGEBRA, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1968603-A2 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | Algebra Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079470-A2 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155729-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155729-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | AADAT, AADAC, AANAT | CA12 2945/4885CA1 3333/4885CA2 3685/4885 |
| US-20100311727-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | AADAT, AADAC, AANAT | CA12 2945/4885CA1 3333/4885CA2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.